Structural and functional basis of cyclooxygenase inhibition

被引：417

作者：

Blobaum, Anna L.

Marnett, Lawrence J.

机构：

[1] Vanderbilt Univ, Sch Med, Dept Biochem, AB Hancock Jr Mem Lab Canc Res, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Sch Med, Dept Chem, Nashville, TN 37232 USA

[3] Vanderbilt Univ, Sch Med, Dept Pharmacol, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA

[4] Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2007年 / 50卷 / 07期

关键词：

D O I：

10.1021/jm0613166

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

[No abstract available]

引用

页码：1425 / 1441

页数：17

共 118 条

[31] A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors [J].

Gierse, JK ;

McDonald, JJ ;

Hauser, SD ;

Rangwala, SH ;

Koboldt, CM ;

Seibert, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (26) :15810-15814

[32] Kinetic basis for selective inhibition of cyclo-oxygenases [J].

Gierse, JK ;

Koboldt, CM ;

Walker, MC ;

Seibert, K ;

Isakson, PC .

BIOCHEMICAL JOURNAL, 1999, 339 :607-614

[33]

Greenberg HE, 2000, J CLIN PHARMACOL, V40, P1509

[34] The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs [J].

Greig, GM ;

Francis, DA ;

Falgueyret, JP ;

Ouellet, M ;

Percival, MD ;

Roy, P ;

Bayly, C ;

Mancini, JA ;

ONeill, GP .

MOLECULAR PHARMACOLOGY, 1997, 52 (05) :829-838

[35] Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities [J].

Grosser, T ;

Fries, S ;

FitzGerald, GA .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (01) :4-15

[36] Role of Val(509) in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents [J].

Guo, QP ;

Wang, LH ;

Ruan, KH ;

Kulmacz, RJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (32) :19134-19139

[37] Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 [J].

Gupta, RA ;

DuBois, RN .

NATURE REVIEWS CANCER, 2001, 1 (01) :11-21

[38]

HAMBERG M, 1967, J BIOL CHEM, V242, P5344

[39] Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis [J].

Hippisley-Cox, J ;

Coupland, C .

BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7504) :1366-1369

[40] Tyrosine-385 is critical for acetylation of cyclooxygenase-2 by aspirin [J].

Hochgesang, GP ;

Rowlinson, SW ;

Marnett, LJ .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2000, 122 (27) :6514-6515

← 1 2 3 4 5 6 7 8 9 10 →